Use of acetylsalicylic acid and its combined forms in real clinical practice

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The first opinion of the possibility of primary prevention of myocardial infarction by salicin derivative – acetylsalicylic acid (ASA), was published back in 1950. Current specialized review provides updated information on the role of ASA in primary and secondary prevention of cardiovascular diseases, as well as some information on the direction in which such kind of prevention could be developed.

The aim of the review: to highlight the role of ASA in the modern real clinical practice of a therapist.

Material and methods. An adaptive version of the literature search is proposed, when it is carried out for each section of the review separately. The following keyword groups were searched in PubMed (MEDLINE), Scopus, eLibrary, and CyberLeninka databases: *acetylsalicylic acid, *aspirin, *mechanism of action, *pharmacokinetics, *pharmacodynamics, *placebo-controlled studies, *efficacy, *safety, *combined forms, *magnesium hydroxide. In Russian-language databases, the query was compiled using the same algorithm and similar terms in Russian. Literature review included 61 sources.

Conclusion. Taking into account the large volume of evidence of efficacy and safety, low-dose ASA should continue to be used as an antithrombotic agent for the prevention of cardiovascular mortality. In modern clinical practice, it is unlikely to be displaced by currently available P2Y12 inhibitors due to the inconclusive demonstration of their superiority over low-dosed ASA.

全文:

受限制的访问

作者简介

Aleksey Borisov

R.R. Vreden National Medical Research Center of Traumatology and Orthopedics of the Ministry of Healthcare of Russia

Email: amborisov@rniito.ru
ORCID iD: 0000-0003-3449-8196
SPIN 代码: 2928-4410

MD, physician – clinical pharmacologist of the Department of clinical pharmacology

俄罗斯联邦, Saint Petersburg

Alina Kasimova

R.R. Vreden National Medical Research Center of Traumatology and Orthopedics of the Ministry of Healthcare of Russia; Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of Russia

编辑信件的主要联系方式.
Email: kasi-alina@yandex.ru
ORCID iD: 0000-0001-6284-7133
SPIN 代码: 3131-4385

MD, PhD (Medicine), associate professor, associate professor of the Department of clinical pharmacology and evidence-based medicine, clinical pharmacologist of the Department of clinical pharmacology

俄罗斯联邦, Saint Petersburg; Saint Petersburg

参考

  1. Fuste V, Sweeny JM. Aspirin: A historical and contemporary therapeutic overview. Circulation. 2011;123(7):768–78. PMID: 21343593. https://doi.org/10.1161/circulationaha.110.963843
  2. Desborough MJR., Keeling DM. The aspirin story – from willow to wonder drug. Br J Haematol. 2017;177(5):674–83. PMID: 28106908. https://doi.org/10.1111/bjh.14520
  3. Fijałkowski Ł, Skubiszewska M, Grześk G, Koech FK, Nowaczyk A. Acetylsalicylic acid-primus inter pares in pharmacology. Molecules. 2022;27(23):8412. PMID: 36500502. PMCID: PMC9738180. https://doi.org/10.3390/molecules27238412
  4. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6921):81– 106. PMID: 8298418. PMCID: PMC2539220.
  5. Kirchner VA, O’Farrell B, Imber C, McCormack L, Northup PG, Song G-W et al.; ERAS4OLT.org Working Group. What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery, or portal vein thrombosis? A systematic review of the literature and expert panel recommendations. Clin Transplant. 2022;36(10):e14629. PMID: 35240723. PMCID: PMC10078564. https://doi.org/10.1111/ctr.14629
  6. Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for prevention of preeclampsia. Drugs. 2017;77(17):1819–31. PMID: 29039130. PMCID: PMC5681618. https://doi.org/10.1007/s40265-017-0823-0
  7. Patrono C, Rodríguez LAG, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–83. PMID: 16319386. https://doi.org/10.1056/nejmra052717
  8. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482–94. PMID: 18077812. https://doi.org/10.1056/nejmra071014
  9. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72(6):1177–84. PMID: 3933848. https://doi.org/10.1161/01.cir.72.6.1177
  10. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366–72. PMID: 7045161. PMCID: PMC370209. https://doi.org/10.1172/jci110576
  11. Patrono C, Morais J, Baigent C, Collet J-P, Fitzgerald D, Halvorsen S et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol. 2017;70(14):1760–76. PMID: 28958334. https://doi.org/10.1016/j.jacc.2017.08.037
  12. Patrignani P, Tacconelli S, Piazuelo E, Di Francesco L, Dovizio M, Sostres C et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost. 2014;12(8):1320–30. PMID: 24942808. https://doi.org/10.1111/jth.12637
  13. Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79. PMID: 23726390. PMCID: PMC3778977. https://doi.org/10.1016/S0140-6736(13)60900-9
  14. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–17. PMID: 11752357. https://doi.org/10.1056/nejmoa003199
  15. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost. 2005;3(8):1597–1602. PMID: 16102024. https://doi.org/10.1111/j.1538-7836.2005.01380.x
  16. Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet J-P et al. Antithrombotic therapy and body mass: An expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672–86. PMID: 29509886. https://doi.org/10.1093/eurheartj/ehy066
  17. Marquis-Gravel G, Stebbins A, Wruck LM, Roe MT, Effron MB, Hammill BG et al. Age and aspirin dosing in secondary prevention of atherosclerotic cardiovascular disease. J Am Heart Assoc. 2024;13(4):e026921. PMID: 38348779. PMCID: PMC11010083. https://doi.org/10.1161/jaha.122.026921
  18. Lanas A, Werz O, Mikhail E. Comparison of gastrointestinal adverse events between fast release tablets and regular acetylsalicylic acid (aspirin) galenics after short-term use: A meta-analysis of randomized clinical trials. Inflammopharmacology. 2023;31(5):2369–81. PMID: 37603157. PMCID: PMC10518280. https://doi.org/10.1007/s10787-023-01264-3
  19. Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT et al. A platelet-inhibitor-drug trial in coronary-artery bypass operations: Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med. 1982;307(2):73–78. PMID: 7045659. https://doi.org/10.1056/nejm198207083070201
  20. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61(2):314–19. PMID: 413839. PMCID: PMC372541. https://doi.org/10.1172/jci108941
  21. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311(19):1206–11. PMID: 6436696. https://doi.org/10.1056/nejm198411083111902
  22. Giaretta A, Rocca B, Di Camillo B, Toffolo GM, Patrono C. In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease. Clin Pharmacol Ther. 2017;102(5):823–31. PMID: 28378909. https://doi.org/10.1002/cpt.694
  23. Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood. 2013;121(10):1701–11. PMID: 23335367. https://doi.org/10.1182/blood-2012-10-429134
  24. Cavalca V, Rocca B, Veglia F, Petrucci G, Porro B, Myasoedova V et al. On-pump cardiac surgery enhances platelet renewal and impairs aspirin pharmacodynamics: Effects of improved dosing regimens. Clin Pharmacol Ther. 2017;102(5):849–58. PMID: 28379623. https://doi.org/10.1002/cpt.702
  25. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595–3603. PMID: 22234683. https://doi.org/10.1182/blood-2011-06-359224
  26. Krasinska B, Paluszkiewicz L, Miciak-Ławicka E, Krasinski M, Rzymski P, Tykarski A, Krasiński Z. The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients – a randomized, controlled trial. Eur J Clin Pharmacol. 2021;77(1):35–43. PMID: 32959110. PMCID: PMC7782434. https://doi.org/10.1007/s00228-020-02997-8
  27. Pareek M, Kristensen SD, Grove EL. Cardiovascular events after discontinuation of low-dose aspirin. J Thorac Dis. 2018;10(1):75–78. PMID: 29600025. PMCID: PMC5863118. https://doi.org/10.21037/jtd.2017.12.48
  28. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al.; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. PMID: 27222591. PMCID: PMC4986030. https://doi.org/10.1093/eurheartj/ehw106
  29. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. PMID: 11786451. PMCID: PMC64503. https://doi.org/10.1136/bmj.324.7329.71
  30. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Muñoz D et al.; ADAPTABLE Team. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384(21):1981–90. PMID: 33999548. PMCID: PMC9908069. https://doi.org/10.1056/nejmoa2102137
  31. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309(7):396–403. PMID: 6135989. https://doi.org/10.1056/nejm198308183090703
  32. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol. 1991;18(7):1587–93. PMID: 1960301. https://doi.org/10.1016/0735-1097(91)90489-v
  33. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313(22):1369–75. PMID: 3903504. https://doi.org/10.1056/nejm198511283132201
  34. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–39. PMID: 8918275. https://doi.org/10.1016/s0140-6736(96)09457-3
  35. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet. 2000;355(9201):337–45. PMID: 10665552.
  36. Bousser M-G, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM et al.; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial. Lancet. 2011;377(9782):2013–22. PMID: 21616527. https://doi.org/10.1016/s0140-6736(11)60600-4
  37. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR et al.; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35–43. PMID: 27160892. https://doi.org/10.1056/NEJMoa1603060
  38. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D et al.; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–49. PMID: 30166073. https://doi.org/10.1016/S0140-6736(18)31858-0
  39. Koo B-K, Kang J, Park KW, Rhee T-M, Yang H-M, Won K-B et al.; HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet, 2021;397(10293):2487–96. PMID: 34010616. https://doi.org/10.1016/S0140-6736(21)01063-1
  40. Chiarito M, Sanz-Sanchez J, Cannata F, Cao D, Sturla M, Panico C et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: A systematic review and meta-analysis. Lancet. 2020;395(10235):1487– 95. PMID: 32386592. https://doi.org/10.1016/S0140-6736(20)30315-9
  41. Gragnano F, Cao D, Pirondini L, Franzone A, Kim H-S, von Scheidt M et al.; PANTHER Collaboration. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82(2):89–105. PMID: 37407118. https://doi.org/10.1016/j.jacc.2023.04.051
  42. Tantry US, Navarese EP, Bliden KP, Gurbel PA. Acetylsalicylic acid and clopidogrel hyporesponsiveness following acute coronary syndromes. Kardiol Pol. 2018;76(9):1312–19. PMID: 30091133. https://doi.org/10.5603/kp.a2018.0159
  43. Khalili M, Lepeytre F, Guertin JR, Goupil R, Troyanov S, Bouchard J, Madore F. Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: A population-based survey. CMAJ Open. 2020;8(1):E41–E47. PMID: 31992558. PMCID: PMC6996036. https://doi.org/10.9778/cmajo.20190105
  44. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646. PMID: 30879355. PMCID: PMC7734661. https://doi.org/10.1161/cir.0000000000000678
  45. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis. JAMA. 2019;321(3):277–87. PMID: 30667501. PMCID: PMC6439678. https://doi.org/10.1001/jama.2018.20578
  46. Rognvaldsson KG, Bjarnason A, Kristinsson K, Bragason HT, Erlendsdóttir H, Þorgeirsson G, Gottfreðsson M. Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia: A long-term nationwide study. J Intern Med. 2022;292(2):321–32. PMID: 35315156. PMCID: PMC9543431. https://doi.org/10.1111/joim.13485
  47. ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39. PMID: 30146931. https://doi.org/10.1056/nejmoa1804988
  48. Wein T, Lindsay MP, Gladstone DJ, Poppe A, Bell A, Casaubon LK et al.; Heart and Stroke Foundation of Canada in collaboration with the Canadian Stroke Consortium. Canadian Stroke best practice recommendations, seventh edition: Acetylsalicylic acid for prevention of vascular events. CMAJ. 2020;192(12):E302–E311. PMID: 32392513. PMCID: PMC7101172. https://doi.org/10.1503/cmaj.191599
  49. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med. 2008;121(1):43–49. PMID: 18187072. https://doi.org/10.1016/j.amjmed.2007.10.002
  50. Patrono C, Rocca B. Nonsteroidal antiinflammatory drugs: Past, present and future. Pharmacol Res. 2009;59(5):285–89. PMID: 19416627. https://doi.org/10.1016/j.phrs.2009.01.011
  51. Gawaz M, Vogel S. Platelets in tissue repair: Control of apoptosis and interactions with regenerative cells. Blood. 2013;122(15):2550–54. PMID: 23963043. https://doi.org/10.1182/blood-2013-05-468694
  52. Kontoghiorghes GJ. The puzzle of aspirin and iron deficiency: The vital missing link of the iron-chelating metabolites. Int J Mol Sci. 2024;25(10):5150. PMID: 38791185. PMCID: PMC11121054. https://doi.org/10.3390/ijms25105150
  53. CURRENT-OASIS 7 Investigators; Mehta SR, Bassand J-P, Chrolavicius S, Diaz R, Eikelboom JW, Fox KAA et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930–42. PMID: 20818903. https://doi.org/10.1056/nejmoa0909475
  54. Miilunpohja S, Jyrkkä J, Kärkkäinen JM, Kastarinen H, Heikkinen M, Paajanen H et al. Discontinuing low-dose acetylsalicylic acid after gastrointestinal bleeding is associated with increased mortality. Scand J Gastroenterol. 2022;57(5):618–24. PMID: 35041575. https://doi.org/10.1080/00365521.2022.2026461
  55. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231–41. PMID: 29475806. PMCID: PMC5842491. https://doi.org/10.1016/S2468-1253(18)30037-2
  56. Hawkey C, Avery A, Coupland CAC, Crooks C, Dumbleton J, Hobbs FDR et al.; HEAT Trialists. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): A randomised, double-blind, placebo-controlled trial. Lancet. 2022;400(10363):1597–1606. PMID: 36335970. https://doi.org/10.1016/S0140-6736(22)01843-8
  57. Yoskovitz GS, Yoskovitz MS, Haim-Pinhas H, Saban M, Pereg D, Wand O et al. Risk factors for major bleeding among patients with chronic kidney disease treated with acetylsalicylic acid. Kidney Blood Press Res. 2024;49(1):1033–40. PMID: 39527927. https://doi.org/10.1159/000542500

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025